Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-04-20

Clinical Trial Update: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial results for trientine tetrahydrochloride in Wilson disease have been completed, with results posted in April 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Trientine tetrahydrochloride (TETA4HCl) (trientine tetrahydrochloride)

Snippet

Sponsor: Orphalan | Conditions: Wilson Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-04-20